Commercialisation

Designing how your asset reaches patients and creates value

We take your late-stage development and deal plans and translate them into a practical route-to-market. That means defining which markets to prioritise, how to think about pricing and access, and whether to go via strategic partners, regional players, or a focused own presence.

From development plan to market plan

We start with your clinical and regulatory strategy, then map how the asset will be evaluated by payers, prescribers, and procurement. We identify priority markets, key segments and centres, and the early signals partners and investors will look for—so commercial questions don’t become a last-minute issue at the deal table.

Partner, channel, and launch choices

Together we evaluate partnering vs. own commercial presence: global pharma, regional specialists, distributors, or hybrid models. We outline launch and early-access concepts, link them to your evidence and resource constraints, and build a high-level roadmap of what needs to happen pre-, during, and post-launch.

Key areas of commercialisation support

• Market & segment prioritisation – Ranking geographies and patient segments by opportunity, feasibility, and strategic relevance.

• Pricing & access thesis (high-level) – Crafting a realistic early view on positioning, value drivers, and payer expectations to guide deals and planning.

• Route-to-market & partner model – Evaluating options across global pharma, regional players, distributors, and co-promotion or co-commercialisation.

• Launch & early-access roadmap – Defining key milestones, enablers, and dependencies from late-stage development to first revenues.

• Alignment with BD & licensing – Ensuring that commercialization scenarios and obligations are reflected in partnering and deal structures.

“A credible path to market is often what turns an interesting asset into a partner’s or investor’s priority.”

With a clear commercialisation view, you can speak to partners and investors not only about what the asset does, but how it can realistically reach patients and generate returns—making your BD, licensing, and capital stories more concrete and convincing.